SphK2 downregulation not only enhances cellular sphingosine levels but also increases WT1 and nephrin expressions, suggesting that the nephroprotective effects of dexamethasone might be mediated through the downregulation of SphK2—a finding particularly beneficial in diabetic nephropathy and other glomerular kidney diseases [49]. This evidence concerns the gene SPHK2 and diabetic kidney disease.